Eris Lifesciences Quarterly Results for Trading Insights
In Mar 2026, Eris Lifesciences (ERIS) reported revenue ₹755 Cr and net profit ₹279 Cr — revenue +6.2% YoY. View ERIS 52-week high low for the annual high/low range and current price position.
ERIS Quarterly Results — Revenue, Profit & EPS Highlights
Eris Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse Eris Lifesciences shareholding analysis to track promoter, FII and institutional holdings.
- Revenue of ₹755 Cr in Mar 2026 (-13.3% vs Jun 2026, +6.2% vs Mar 2025)
- Net Profit of ₹279 Cr in Mar 2026 (+95.1% vs Jun 2026, +173.5% vs Mar 2025)
- EBITDA of ₹270 Cr in Mar 2026 (-8.2% vs Jun 2026)
- Operating Margin of 36.0% in Mar 2026 (+2.0pp vs Jun 2026)
- Earnings Per Share of ₹20.60 in Mar 2026 (+100.4% vs Jun 2026)
Eris Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ERIS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 755 | 871 | 793 | 711 | 775 | -13.3% | 6.2% |
| Net Profit (₹ Cr) | 279 | 143 | 135 | 102 | 125 | - | - |
| EBITDA (₹ Cr) | 270 | 294 | 289 | 258 | 279 | - | - |
| EPS (₹) | 20.60 | 10.28 | 8.82 | 6.90 | 8.66 | - | - |
| Operating Margin (%) | 36.0% | 34.0% | 36.0% | 36.0% | 36.0% | - | - |
ERIS Share Price Trend — 1-Year Movement Across Quarterly Results
Eris Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Eris Lifesciences share price today.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ERIS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Eris Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores